Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;12(6):3199-3210.
doi: 10.1007/s40123-023-00816-8. Epub 2023 Sep 25.

Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye

Affiliations

Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye

Pasquale Viggiano et al. Ophthalmol Ther. 2023 Dec.

Abstract

Introduction: The aim of this work is to utilize swept-source optical coherence tomography angiography (SS-OCTA) to assess the long-term changes in the choroidal and choriocapillaris (CC) layers of the fellow unaffected eye of patients with unilateral resolved chronic central serous chorioretinopathy (cCSC) following treatment with continuous oral eplerenone (EPL).

Methods: The study included 35 patients with cCSC and subretinal fluid (SRF) in one eye. SS-OCTA imaging was performed on the fellow cCSC eyes at baseline, 6 months, and 12 months during eplerenone therapy. CC OCT angiography was analyzed to determine the percentage of choriocapillaris flow deficits (FD%), the number of flow deficits (FDn), and the average area of flow deficits (FDa).

Results: The results demonstrated significant changes in CC flow deficits from baseline to follow-up visits. Specifically, there was a significant decrease in FD% from 28.9 ± 2.2% at baseline to 26.4 ± 1.9% at 6 months (p = 0.023), and further to 24.9 ± 1.7% at 12 months (p = 0.001). Additionally, the FD area gradually contracted over the follow-up period (p < 0.05). Conversely, there was a significant increase in the number of flow deficits compared to baseline (p < 0.05). No statistically significant changes were observed in best-corrected visual acuity (BCVA) at the follow-up visits (p > 0.05).

Conclusions: The findings of this study demonstrated long-term reperfusion of the choriocapillaris in unaffected fellow cCSC eyes during continuous oral eplerenone therapy. The beneficial effects of eplerenone therapy were observed after 6 months and maintained at 1 year. These results suggest that specific mineralocorticoid receptor (MR) antagonists may be effective in promoting choriocapillaris recovery in the unaffected eyes of patients with cCSC.

Keywords: Central serous chorioretinopathy; Choriocapillaris layer; Choroidal perfusion; Choroidal vascular changes; Optical coherence tomography angiography.

PubMed Disclaimer

Conflict of interest statement

Pasquale Viggiano, Giacomo Boscia, Enrico Borrelli, Francesco Boscia, Lisa Toto, Maria Oliva Grassi, Federica Evangelista, Ermete Giancipoli and Giovanni Alessio have nothing to disclose.

Figures

Fig. 1
Fig. 1
Choriocapillaris swept-source optical coherence tomography angiography (SS-OCTA) scans in fellow chronic central serous chorioretinopathy (cCSC) pachychoroid eye continuously treated with eplerenone. SS-OCTA image of the choriocapillaris (CC) in unaffected cCSC pachychoroid eye was used to analyze choriocapillaris flow deficits parameters. The CC images were binarized by the Phansalkar method. Scans were acquired at baseline visit, and also at 6 months and 12 months. The figure shows the CC reperfusion area throughout the follow-up (white circle)

References

    1. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118. doi: 10.1016/j.preteyeres.2015.05.003. - DOI - PubMed
    1. Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol. 2016;94:321–325. doi: 10.1111/aos.12779. - DOI - PubMed
    1. Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5:2. doi: 10.1167/tvst.5.2.2. - DOI - PMC - PubMed
    1. Toto L, Ruggeri ML, Evangelista F, Viggiano P, D’Aloisio R, De Nicola C, et al. Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy. Eye (Lond) 2022;37(6):1214–1218. doi: 10.1038/s41433-022-02091-6. - DOI - PMC - PubMed
    1. Sacconi R, Borrelli E, Querques G. Eplerenone for chronic central serous chorioretinopathy. Lancet (London, England) 2020;396:1556. doi: 10.1016/S0140-6736(20)31610-X. - DOI - PubMed

LinkOut - more resources